Weekly Recap: Sono-Tek (SOTK) medical revenue surge and Q1 EPS shortfall
Thời gian đọc: dưới 1 phút
Sono-Tek Corporation (NASDAQ:SOTK) reported explosive medical sales—H1 fiscal 2027 medical revenue surged 289% to $7.1M and Q2 rose 209% to $3.11M on drug-eluting balloon and stent-coating system shipments, even as Q1 EPS missed forecasts at $0.02 versus $0.03 a year ago.
Previous Week Recap
- Sono-Tek Medical Revenue Surge: Sono-Tek (SOTK) medical sales jumped: H1 fiscal 2027 medical revenue +289% to $7.1M; Q2 medical revenue +209% to $3.11M, driven by drug-eluting balloon and stent-coating system shipments. 2 nguồn
- Q1 EPS Misses estimates: Sono-Tek (SOTK) Q1 EPS $0.02 vs $0.03 year-ago; missed analyst forecast of $0.04. Reuters
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.